Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2021 · 10-Q
Revenue$584.00K$584.00K−64.6% vs Q1 2020 Net Income-$1.88M-$1.88MN/M vs Q1 2020 EPS Diluted-$0.05-$0.05N/M vs Q1 2020 Gross Profit$46,000+12.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flow-$3,988,000N/M Free Cash Flowderived-$4,932,000N/M Margins · derivedGross margin7.9%+5.4 pt vs Q1 2020
Operating margin-330.7%−242.4 pt vs Q1 2020
Net margin-322.3%−238.6 pt vs Q1 2020
ended Jun 30, 2020 · filed Aug 19, 2020 · 50 d after period end